CN113710317A - 含有d-阿洛糖和/或d-阿洛酮糖而成的腹膜透析液的渗透压调节剂 - Google Patents

含有d-阿洛糖和/或d-阿洛酮糖而成的腹膜透析液的渗透压调节剂 Download PDF

Info

Publication number
CN113710317A
CN113710317A CN202080024937.6A CN202080024937A CN113710317A CN 113710317 A CN113710317 A CN 113710317A CN 202080024937 A CN202080024937 A CN 202080024937A CN 113710317 A CN113710317 A CN 113710317A
Authority
CN
China
Prior art keywords
glucose
psicose
peritoneal dialysis
allose
osmotic pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080024937.6A
Other languages
English (en)
Chinese (zh)
Inventor
南野哲男
尾崎太郎
吉原明秀
何森健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Storas Holding Co
Kagawa University NUC
Original Assignee
Kagawa University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagawa University NUC filed Critical Kagawa University NUC
Publication of CN113710317A publication Critical patent/CN113710317A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
CN202080024937.6A 2019-03-29 2020-03-10 含有d-阿洛糖和/或d-阿洛酮糖而成的腹膜透析液的渗透压调节剂 Pending CN113710317A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-065393 2019-03-29
JP2019065393 2019-03-29
PCT/JP2020/010232 WO2020203086A1 (ja) 2019-03-29 2020-03-10 Ｄ－アロースおよび／またはｄ－アルロースを含有してなる腹膜透析液の浸透圧調整剤

Publications (1)

Publication Number Publication Date
CN113710317A true CN113710317A (zh) 2021-11-26

Family

ID=72668623

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080024937.6A Pending CN113710317A (zh) 2019-03-29 2020-03-10 含有d-阿洛糖和/或d-阿洛酮糖而成的腹膜透析液的渗透压调节剂

Country Status (7)

Country Link
US (1) US20220175931A1 (https=)
EP (1) EP3950057A4 (https=)
JP (1) JPWO2020203086A1 (https=)
CN (1) CN113710317A (https=)
BR (1) BR112021016283A2 (https=)
CA (1) CA3134085A1 (https=)
WO (1) WO2020203086A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008669A (ja) * 2004-05-24 2006-01-12 Kagawa Univ 植物または微生物への希少糖の使用
JP2007051135A (ja) * 2005-07-20 2007-03-01 Teikoku Seiyaku Co Ltd Ｄ−アロースの血糖上昇抑制効果の利用
JP2009269887A (ja) * 2008-05-09 2009-11-19 Kagawa Univ 希少糖を含有する腹膜劣化抑制剤、腹膜透析液および腹膜透析法
CN103052389A (zh) * 2010-07-23 2013-04-17 学校法人东海大学 腹膜透析患者用口服药物组合物及其用法
EP2723722A1 (en) * 2011-06-27 2014-04-30 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl (2,3,4,5,6-pentahydroxyhexyl) amino) ethoxy) phenyl) butyl) carbamimidoyl) pyrazine-2-carboxamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4943839B1 (https=) 1968-06-10 1974-11-25
JPS5330976B1 (https=) 1971-07-22 1978-08-30
JPS5317055B2 (https=) 1972-08-09 1978-06-06
US3991349A (en) 1975-01-03 1976-11-09 Westinghouse Electric Corporation Droop adjustable control apparatus for direct current motor drives
JPS5316164A (en) 1976-07-27 1978-02-14 Aisin Seiki Co Ltd Fluid coupling device
JPS589701B2 (ja) 1977-06-04 1983-02-22 株式会社栗本鉄工所 廃棄物処理装置
JPH1171273A (ja) 1997-08-29 1999-03-16 Terumo Corp 腹膜透析液
JP4473980B2 (ja) 1999-06-24 2010-06-02 株式会社林原生物化学研究所 糖質複合体結晶とその製造方法
JP4499882B2 (ja) 2000-07-07 2010-07-07 株式会社林原生物化学研究所 Ｄ−キシロース・イソメラーゼを用いるアルドヘキソースの製造方法
JP4882054B2 (ja) 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
CN1668735A (zh) * 2002-05-22 2005-09-14 国立大学法人香川大学 稀有糖的生物活性的利用方法及配合了稀有糖的组合物
JP2005102503A (ja) 2003-01-10 2005-04-21 Kagawa Univ 新しい触媒機能を有するｌ−ラムノースイソメラーゼの遺伝子配列およびその用途
JP5421512B2 (ja) * 2004-01-30 2014-02-19 帝國製薬株式会社 Ｄ−プシコースの血糖上昇抑制効果の利用
JP4724824B2 (ja) 2004-03-19 2011-07-13 国立大学法人 香川大学 希少糖のｔリンパ球の増殖抑制への使用
US7691619B2 (en) 2004-08-24 2010-04-06 Rare Sugar Production Technical Research Laboratories, Llc Sequence of thermotolerant L-rhamnose isomerase gene and use of the same
EP1864669B1 (en) 2005-03-23 2018-06-27 Rare Sugar Production Technical Research Laboratories, LLC Application of d-psicose to suppression of abnormal circadian increase in blood glucose level
KR100744479B1 (ko) 2005-06-01 2007-08-01 씨제이 주식회사 사이코스 에피머화 효소에 의한 사이코스의 생산 방법
US8440619B2 (en) 2005-08-31 2013-05-14 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of D-allose
JP5997693B2 (ja) 2011-07-06 2016-09-28 松谷化学工業株式会社 アルスロバクターグロビホルミスの生産する酵素

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008669A (ja) * 2004-05-24 2006-01-12 Kagawa Univ 植物または微生物への希少糖の使用
JP2007051135A (ja) * 2005-07-20 2007-03-01 Teikoku Seiyaku Co Ltd Ｄ−アロースの血糖上昇抑制効果の利用
JP2009269887A (ja) * 2008-05-09 2009-11-19 Kagawa Univ 希少糖を含有する腹膜劣化抑制剤、腹膜透析液および腹膜透析法
CN103052389A (zh) * 2010-07-23 2013-04-17 学校法人东海大学 腹膜透析患者用口服药物组合物及其用法
EP2723722A1 (en) * 2011-06-27 2014-04-30 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl (2,3,4,5,6-pentahydroxyhexyl) amino) ethoxy) phenyl) butyl) carbamimidoyl) pyrazine-2-carboxamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
董会钰 王广珠: "基础化学", 31 January 2019, 中国医药科技出版社, pages: 11 *

Also Published As

Publication number Publication date
JPWO2020203086A1 (https=) 2020-10-08
BR112021016283A2 (pt) 2021-10-13
EP3950057A4 (en) 2022-12-28
CA3134085A1 (en) 2020-10-08
EP3950057A1 (en) 2022-02-09
US20220175931A1 (en) 2022-06-09
WO2020203086A1 (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
US6492336B1 (en) Peritoneal dialysis fluid
CA1182046A (en) Pharmaceutical composition for the treatment of diabetes mellitus
JP5507609B2 (ja) 腹膜透析液
Coles et al. A randomized controlled trial of a bicarbonate and a bicarbonate/lactate-containing dialysis solution in CAPD
US4980374A (en) Dialysis and rinsing solution for intraperitoneal administration with antimicrobial activity
WO2012041898A1 (en) Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
JP4638106B2 (ja) 医薬的使用のための溶液中における浸透圧剤としての、ｌ−カルニチンおよびそのアルカノイル誘導体の使用
JP2011500578A (ja) ピロホスフェートを含む滅菌透析溶液
EP0078832A1 (en) DIALYSIS SOLUTION CONTAINING GLYCEROL.
CN110812364A (zh) 半乳寡糖及其衍生物在作为SGLTs抑制剂中的应用
CN104622896A (zh) 一种钠钾镁钙葡萄糖注射液的制备方法
KR101434329B1 (ko) 체온 저하 억제제
AU682609B2 (en) Dialysis fluid containing peptides obtained from casein as osmotic agents and bicarbonate ions as buffering agents
JP2009269887A (ja) 希少糖を含有する腹膜劣化抑制剤、腹膜透析液および腹膜透析法
US20130197428A1 (en) Peritoneal Dialysis Method
JP4766653B2 (ja) 眼科用医薬組成物
CN113710317A (zh) 含有d-阿洛糖和/或d-阿洛酮糖而成的腹膜透析液的渗透压调节剂
Shockley et al. New solutions for peritoneal dialysis in adult and pediatric patients
EP3212199B1 (en) Pharmaceutical compositions containing steviosides
JPH1094598A (ja) 腹膜透析液
WO2002081005A2 (en) Peritoneal dialysis fluid
JPH1149671A (ja) 腹膜透析液
JP4049278B2 (ja) 腸内代謝改善剤
CN101152204A (zh) 氯法拉滨的静脉给药制剂及其制备方法
CN102596982B (zh) 腹膜肥厚抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231220

Address after: Kagawa

Applicant after: NATIONAL UNIVERSITY CORPORATION KAGAWA University

Applicant after: Storas Holding Co.

Address before: Kagawa

Applicant before: NATIONAL UNIVERSITY CORPORATION KAGAWA University